# NVP Healthcare clinical trials: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with NVP Healthcare as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by NVP Healthcare: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/nvp-healthcare

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 7, 2025 | NCT06761066 | Efficacy and Safety of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease | NVP Healthcare | Not applicable | Enrolling by invitation | Alzheimer Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06761066) |
| May 12, 2023 | NCT05856487 | To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients | NVP Healthcare | Phase 3 | Unknown | Cardiovascular Diseases | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05856487) |
| February 13, 2023 | NCT05725252 | To Evaluate the Safety and the Pharmacokinetics of NVP-2203 | NVP Healthcare | Phase 1 | Completed | Healthy Volunteers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05725252) |
| April 29, 2022 | NCT05354713 | NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers (BE) | NVP Healthcare | Phase 1 | Completed | Healthy Volunteers | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05354713) |
| December 2, 2021 | NCT05141110 | Evaluation of Pharmacokinetic and Safety of NVP-1705 and NVP-1705-R in Healthy Subjects | NVP Healthcare | Phase 1 | Completed | Healthy Subjects | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05141110) |
| August 26, 2021 | NCT05023031 | Evaluation of Pharmacokinetic and Safety of NVP-2102 and NVP-2102-R in Healthy Subjects | NVP Healthcare | Phase 1 | Completed | Healthy Subjects | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05023031) |
| July 14, 2021 | NCT04961905 | Pharmacokinetic Characteristics and Safety After Administration of NVP-2002 | NVP Healthcare | Phase 1 | Completed | Healthy | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04961905) |
| May 27, 2021 | NCT04905342 | NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers | NVP Healthcare | Phase 1 | Completed | Healthy Volunteers | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04905342) |
| March 3, 2021 | NCT04780386 | Compare the Pharmacokinetics of NVP-1805 and Coadministration of NVP-1805-R1 With NVP-1805-R2 | NVP Healthcare | Phase 1 | Completed | Healthy | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04780386) |
| November 29, 2019 | NCT04181437 | Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2 | NVP Healthcare | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04181437) |
| September 10, 2019 | NCT04082975 | Efficacy and Safety of NVP-1203 and NVP-1203-R in Patients With Acute Low Back Pain | NVP Healthcare | Phase 3 | Completed | Acute Low Back Pain | 421 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04082975) |
| January 14, 2019 | NCT03802526 | Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2 | NVP Healthcare | Phase 1 | Completed | Healthy | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03802526) |
| November 14, 2017 | NCT03341832 | Efficacy and Safety of NVP-1203 in Patients With Acute Low Back Pain | NVP Healthcare | Phase 2 | Completed | Acute Low Back Pain | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03341832) |
| November 13, 2017 | NCT03340480 | The Food Effect on the Pharmacokinetics of NVP-1402 | NVP Healthcare | Phase 1 | Completed | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03340480) |
| July 18, 2017 | NCT03220399 | Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2 | NVP Healthcare | Phase 1 | Withdrawn | Healthy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03220399) |
| September 13, 2016 | NCT02897726 | A Study to Evaluate the Safety and Pharmacokinetics of NVP-1402 | NVP Healthcare | Phase 1 | Completed | Healthy | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02897726) |
| November 13, 2014 | NCT02289430 | to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers | NVP Healthcare | Phase 1 | Completed | Healthy | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02289430) |
| November 13, 2014 | NCT02289404 | A Study to Evaluate the Food Effect on the Pharmacokinetics of NVP-1203 | NVP Healthcare | Phase 1 | Completed | Healthy | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02289404) |
| November 13, 2014 | NCT02289274 | Study to Compare Pharmacokinetic Characteristics of Eperisone and Aceclofenac With NVP-1203 | NVP Healthcare | Phase 1 | Withdrawn | Healthy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02289274) |
| January 8, 2014 | NCT02029625 | Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe | NVP Healthcare | Phase 1 | Completed | Dyslipidemia | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02029625) |
| June 25, 2013 | NCT01885520 | Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Eperisone HCl SR Tablet 75mg | NVP Healthcare | Phase 1 | Completed | Low Back Pain | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01885520) |
| January 25, 2013 | NCT01775566 | Clinical Trial to Compare the Pharmacokinetics and Safety of Eperisone HCl SR Tablet 75mg and Myonal Tablet 50mg | NVP Healthcare | Observational | Completed | Low Back Pain | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01775566) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 17 |
| Phase 2 | 1 |
| Phase 3 | 2 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 18 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Low Back Pain | 2 |
| Dyslipidemias | 1 |
| Alzheimer Disease | 1 |
| Cardiovascular Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Engineering schools in the United States](https://specstream.ai/data/businesses/engineering-schools/united-states)
- [B2B science and technology companies in the United States](https://specstream.ai/data/businesses/b2b-science-and-technology-companies/united-states)
- [Speech training companies in the United States](https://specstream.ai/data/businesses/speech-training-companies/united-states)
- [Metal plating companies in the United States](https://specstream.ai/data/businesses/metal-plating-companies/united-states)
- [Fastener suppliers in the United States](https://specstream.ai/data/businesses/fastener-suppliers/united-states)
- [Beauty product suppliers in the United States](https://specstream.ai/data/businesses/beauty-product-suppliers/united-states)
